TABLE 11 Protective Efficacy (PE) and Reported 95% Confidence Intervals (CI) for Outcomes During the 5 Months After Last Dose of SP or Placebo

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Overall

Number of Subjects

 

 

 

 

 

 

 

Placebo

344

1216

755

159

446

561

 

IPTi-SP

344

1197

748

162

459

556

 

Episodes of Clinical Malaria

 

 

 

 

 

 

 

Placebo

87

443

191

298

24

436

 

IPTi-SP

62

436

192

301

34

442

 

% PE

30

0

−6

−3

−36

0

0

95 CI (%)

(1, 51)

(−19, 16)

(−39, 19)

(−21, 12)

(−146, 25)

(−19, 15)

(−10, 9)

Episodes of Hospitalization with Malaria Parasites

 

 

 

 

 

 

 

Placebo

21

32

32

8

NR

4

 

IPTi-SP

18

36

42

12

NR

7

 

% PE

15

−14

−32

−46

NR

−74

−20

95 CI (%)

(−65, 56)

(−96, 33)

(−114, 18)

(−258, 40)

NR

(−496, 49)

(−60, 10)

Episodes of All-Cause Hospital Admissions

 

 

 

 

 

 

 

Placebo

68

117

146

17

13

13

 

IPTi-SP

71

134

138

28

14

22

 

% PE

−5

−16

8

−61

−1

−74

−11

95 CI (%)

(−47, 25)

(−53, 12)

(−26, 33)

(−194, 12)

(−116, 52)

(−264, 16)

(−30, 6)

Subjects with Anemia

 

 

 

 

 

 

 

Placebo

26

60

43

19

113

259

 

IPTi-SP

15

68

39

20

415

248

 

% PE

42

−15

8

−4

−12

3

2

95 CI (%)

(−7, 69)

(−69, 21)

(−40, 40)

(−27, 14)

(−133, 46)

(−10, 15)

(−8, 11)

NOTE: NR: Not reported.

SOURCE: Compiled from data in the report of the Consortium’s Statistical Working Group (IPTi Consortium, 2007b).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement